Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast

Clinics

Volumn 68, Issue 5, 2013, Pages 674-678

  Perez, Amanda Arantes ^a   Rocha, Rafael Malagoli ^b   Balabram, Débora ^a   Souza, Átila da Silva ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Ductal Carcinoma in situ; Immunoprofile; Molecular Phenotype; Molecular Profile

Indexed keywords

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CLASSIFICATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KERATIN-5; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84878470881     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)15     Document Type: Article

References (29)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747-52, http://dx.doi.org/10.1038/35021093.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74, http://dx.doi.org/10.1073/pnas.191367098.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23, http://dx.doi.org/10.1073/pnas.0932692100.
4. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006; 208(4):495-506, http://dx.doi.org/10.1002/path.1916.
5. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50(4):434-38, http://dx.doi.org/10.1111/j.1365-2559.2007.02638.x.
6. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74, http://dx.doi.org/10.1158/1078-0432.CCR-04-0220.
7. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-71, http://dx.doi.org/10.1038/ modpathol.3800528.
8. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447(4):688-94, http://dx.doi.org/10.1007/s00428-005-0010-7.
9. Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology. 2008;52(1):108-18.
10. Silva F, Carvalho S, Milanezi F, Schmitt FC. Basal-like carcinoma of the breast. Acta Med Port. 2008;21(4):373-78.
11. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. 2007;14(5):358-73, http:// dx.doi.org/10.1097/PAP.0b013e31814b26fe.
12. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999;187(4):396-402, http://dx.doi.org/10.1002/(SICI)1096-9896(199903)187:4,396::AIDPATH286.3.0. CO;2-L.
13. Schnitt SJ, Allred C, Britton P, Ellis IO, Lakhani SR, Morrow M, et al. Ductal carcinoma in situ. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO Classification of Tumours of the Breast. IARC: Lyon; 2012.
14. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol. 1997;28(8):967-73, http://dx.doi.org/10. 1016/S0046-8177(97)90013-7.
15. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(7):907-22.
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
17. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197-204, http://dx.doi.org/10.1016/j.humpath. 2006.08.017.
18. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502, http://dx.doi.org/10.1001/ jama.295.21.2492.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74, http://dx.doi.org/10. 2307/2529310.
20. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10(4):R67, http://dx.doi. org/10.1186/bcr2128.
21. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-41.
22. O'Sullivan MJ, Morrow M. Ductal carcinoma in situ-current management. Surg Clin N Am. 2007;87(2):333-51.
23. Paredes J, Lopes N, Milanezi F, Schmitt FC. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007;450(1):73-80, http://dx.doi.org/10.1007/ s00428-006-0334-y.
24. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19(5):617-21, http://dx.doi.org/10.1038/modpathol.38005 70.
25. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19(11):1506-11.
26. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104(1):120-27, http://dx.doi.org/ 10.1038/sj.bjc.6606021.
27. Carvalho FM, Bacchi LM, Santos PPC, Bacchi CE. Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. Clinics. 2010;65(10):1033-36, http://dx.doi.org/10.1590/ S1807-59322010001000019.
28. Kurbel S. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumor Biol. 2012. Dec 4. [Epub ahead of print].
29. Allred DC, Clark GM, Molina R, Andon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23(9):974-79, http://dx.doi.org/10. 1016/0046-8177(92)90257-4.